EGFR and non-small cell lung carcinoma: Emerging 1L treatment strategies that aim to improve overall outcomes in patients with advanced cEGFRm NSCLC include osimertinib in combination with platinum-based doublet chemotherapy, and the bispecific EGFR and MET antibody, amivantamab, in combination with the 3rd generation EGFR TKI, lazertinib [11,23].